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Abstract
Background: Invasive mechanical ventilation (IMV) has been previously associated with a poor outcome for patients with
cystic fibrosis (CF), but with improved survival and the availability of lung transplantation intensive care unit (ICU) admission
is being increasingly considered. This study aimed to review the outcomes of adult CF patients admitted to ICU, and to identify
factors that may have influenced outcomes. Methods: A retrospective audit was conducted of CF patients admitted to ICU.
Anthropometric data, spirometry, nutritional status, sputum microbiology, arterial blood gas tensions, and mode of ventilation used
were recorded. Immediate and 1-year survival and lung transplantation utilisation were recorded. Results: Twenty patients were
admitted to ICU and nine (45%) survived to hospital discharge. Five of the nine survivors had potentially reversible conditions.
Four patients admitted with respiratory exacerbations alone who survived, were maintained on non-invasive ventilation (NIV).
The relative risk of deaths for patients with a BMI-18 and a FEV -24% predicted were 3.25 (1.27–3.25), and 3.68(1.11–1
16.33), respectively. Conclusions: The outcome of patients with CF admitted to ICU has improved, with 45% of the patients in
this study surviving to hospital discharge. Five of these survivors underwent successful lung transplantation. Long-term use of
NIV post discharge may have contributed to this favourable outcome. A BMI-18 and FEV -24% predicted were associated1
with a significantly higher relative risk of death.
 2003 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Cystic fibrosis is the commonest life threatening
autosomal recessive genetic disorder amongst Cauca-
sians. In the past invasive mechanical ventilation (IMV)
has been discouraged in CF because of poor outcomes
documented in a 1978 review w1x.
Since that report, the prognosis of patients with CF
has improved. In Australia, the median survival for
adults with CF in 1999 was 32 years for men and 25
years for women w2x. There are many factors which
have contributed to this improvement, including
improved pancreatic enzyme supplementation and nutri-
tional management w3x, advances in antibiotic therapy
w4x, and advances in physiotherapy techniques w5,6x.
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However, it is the widespread availability of lung
transplantation which offers at least the potential for
substantial increases in survival w7–9x. Non-invasive
ventilation (NIV) has also become available and is
useful in managing acute, or acute on chronic respiratory
failure in patients with CF w10,11x. Hodson et al. looked
in particular at the use of NIV in patients awaiting
transplantation and found it to be a useful bridge to
transplantation. Subsequently, in their retrospective
review of 113 patients Madden et al. w12x found that
particularly in patients who have been accepted, or are
being evaluated for lung transplantation, NIV offers the
possibility of prolonging survival until transplantation
can occur.
These developments have prompted reconsideration
of the use of intensive care units (ICUs) and IMV for
patients with CF. A number of groups w13–15x have
found that infants and young children (-5 years)
requiring IMV due to acute respiratory failure have a
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favourable prognosis. Berlinksi’s group w15x, however,
found that the patients older than 4 years requiring IMV
due to acute respiratory failure still had a high mortality
rate.
Recently, Sood et al. w16x, reviewed the outcomes of
adults with CF who had been admitted to their ICU
since the development of their lung transplant program
and reported a 55% survival rate. The vast majority of
these patients (17y23) received lung transplants and 14
were alive 12 months later. Importantly eight of these
17 patients underwent lung transplantation while still
being mechanically ventilated. This study did not find
that any particular factors such as sex, body mass index,
or respiratory microbiology correlated with survival. At
our institution IMV is considered to be a contraindica-
tion to lung transplantation, due to data suggesting that
mechanically ventilated recipients of lung transplanta-
tion have a worse outcome w7,17x.
Our hypothesis was that the survival for patients
admitted to ICU has improved compared to the report
by Davis 25 years ago, and our aim was to confirm
this, as well as identifying any factors which could
influence outcome.
2. Materials and methods
The adult CF clinic at Royal Prince Alfred Hospital
(RPAH) provides care for the majority of adults with
CF in the state of New South Wales, Australia. The
clinic has grown over the last 15 years as the prognosis
of patients with CF has improved. Since the CF clinic
started 298 patients have attended in total, with the
clinic population including 192 patients in 2002. This
figure includes 35 patients alive post transplantation.
Over the 2-year period 2001–2002 there were 140
inpatient admissions (78 in 2001, 62 in 2002). In
addition since 1989, 57 of the patients have undergone
lung transplantation, with 56 of these being since 1992.
For the purposes of this study, the medical records of
all adults with a diagnosis of CF admitted to the RPAH
ICU over the time period from 1988 to 13 April 2003
were identified, and retrospectively reviewed.
The diagnosis of CF, had been made in early infancy
or childhood, on the basis of characteristic clinical
manifestations, and either a sweat test or cystic fibrosis
genotype. Demographic data (age, sex), severity of
disease (body mass index (BMI), FEV % predicted1
(Forced Expiratory Volume in 1 s, percentage of pre-
dicted value based on age and height), primary diagnosis
at admission, number of days in ICU, mode of ventila-
tion, mask or intubated ventilated days, complications
(pneumothorax, massive haemoptysis), length of stay
(LOS) in ICU and total LOS, and outcomes, were
recorded from medical records.
In this study, the definition of a respiratory exacer-
bation requiring parenteral antibiotics was that of Fuchs
et al. w18x, namely any 4 of the following 12 signs or
symptoms: change in sputum; new or increased hemop-
tysis; increased cough; increased dyspnea; malaise,
fatigue, or lethargy; temperature above 38 8C; anorexia
or weight loss; sinus pain or tenderness; change in sinus
discharge; change in physical examination of the chest;
decrease in pulmonary function by 10% or more from a
previously recorded value; or radiographic changes
indicative of pulmonary infection. A respiratory deteri-
oration (RD) was defined as any event that led to a
decline in respiratory status, and included exacerbations,
as well as pneumothoraces, massive haemoptysis and
allergic reactions.
The FEV recorded was the most recent measurement,1
either on admission to hospital, or the last outpatients
visit or last hospital discharge spirometry prior to this
admission. The spirometry recorded had been performed
within 2 months of the ICU admission in all but three
patients. The sputum microbiology results were those
from samples collected during or closest to hospital
admission. The outcomes recorded were survival to
hospital discharge, lung transplantation, survival 1 year
after ICU discharge. All analyses were based on the
total number of patients.
The relative risk of death was calculated for patients
with an FEV (% predicted) -24% and those with a1
BMI of -18. The relationship of survival to arterial
carbon dioxide tension (P CO ) was evaluated with thea 2
Fisher exact test.
3. Results
Twenty adult patients (12 males ranging in age from
19 to 35 (mean"S.D. 27"5 years), and eight females
ranging in age from 18 to 39 (mean 26"7 years)) were
admitted to ICU over the 15-year period. Three patients
were admitted twice, and one patient was admitted to
ICU three times during the hospital admission. Eighteen
of the 20 received IMV. Fifteen of the 20 (75%) were
admitted with respiratory deteriorations. Three patients
were admitted with CF related liver disease, two of
these with variceal bleeding, and one for intractable
ascites. One patient was admitted with benign intracra-
nial hypertension, and another following an overdose of
recreational drugs.
Tables 1 and 2 show the characteristics of the survi-
vors and those who died, respectively. They highlight
the demographic information (age, sex, BMI), disease
related data (manifestations, lung function, sputum
microbiology), reason for admission, the modes of
ventilation and length of stay in ICU and in hospital of
the two groups. In addition Table 1 shows the number
of patients who underwent lung transplantation and the
timing of this in relation to the hospital admission.
Nine of the 20 patients (45%) survived the ICU
admission and were discharged from hospital, and sur-
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Table 1
Patients who survived – characteristics and outcomes
Pt Sex Age FEV %1 BMI Reason for ICU CF related Sputum Micro LOS ICU Total Type of Use long term Lung Tx and
No. years predicted admission complications (daysy LOS acute NIV timing
admission) (days) ventilation post DyC
1 M 25 24 23 Resp exac Lung Ps aer & 17, 8, 3 113 IMV twice Lung tx as Yes,
pancreatic insufficiency Citrobacter freundii (1st and 3rd inpatient Immediately
IDDM time) and NIV
2 M 29 18 18 Resp exac Lung Ps aer 1, 2 24 IMV twice Yes No
pancreatic insufficiency Nocturnal NIV
3 M 30 15 19 Resp exac Lung Burholderia 13 63 NIV and Yes Yes, 1 year
pancreatic insufficiency picketti IMV Nocturnal NIV later
IDDM Aspergillus in ICU
Fumigatus
4 F 24 25 22 Resp exac Lung Ps aer 51 132 IMV and Yes Yes, 3 year later
@ 26y40 pancreatic insufficiency NIV Nocturnal NIV
pregnant Gestational IDDM
5 F 31 28 22 Anaphylaxis Lung Ps aer, 1, 1 14 IMV (1st No Yes, 1 year later
pancreatic insufficiency time)
Arthritis
6 M 32 38 27 Bilateral Lung Ps aer 1 15 Nil No Yes, 2 year later
Pneumothorax pancreatic insufficiency
7 M 34 31 18 Overdose Lung Ps aer 3 11 IMV No No
pancreatic insufficiency
8 F 20 73 18 Haematemesis Lung Ps aer 5 10 IMV No No, on WyL
pancreatic insufficiency heart, lung liver
Cirrhosis and Portal Htn Tx 7 year later
(8y2003)
9 M 24 75 23 Haematemesis Lung Ps aer 6 25 IMV No No
pancreatic insufficiency
Cirrhosis and Portal Htn
IDDM
Pt No – Patient Number, Resp Exac – Respiratory Exacerbation, IDDM – Insulin Dependent Diabetes Mellitus, Portal Htn-Portal Hypertension, Ps aer – Pseudomonas aeruginosa, DyC –
discharge, Tx – transplant, WyL – waiting list, IMV – Invasive Mechanical Ventilation, NIV – Non-invasive ventilation.
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Table 2
Patients who died-demographic, disease severity and treatment data
Pt Sex Age FEV %1 BMI Reason for ICU CF related Sputum Microbiology LOS ICU Total LOS Type of acute
No years predicted admission complications (days) (days) ventilation
10 M 20 23 17 Resp exac Lung Ps aer 7 8 * IMV
pancreatic insufficiency
11 M 25 17 14 Resp exac Lung Ps aer and S aureus 16 17 IMV
pancreatic insufficiency
12 M 26 9 15 Resp exac Lung Ps aer 13 16 NIV and IMV
pancreatic insufficiency
13 M 20 34 21 Resp exac Lung Ps aer 5 7 * IMV
pancreatic insufficiency
14 F 24 6 14 Resp exac Lung Ps aer 1, 1 10 CPAP 1st time
pancreatic insufficiency NIV 2nd time
15 F 22 27 17 Resp exac Lung Ps aer on admission 1, 10 54 CPAP and IMV
pancreatic insufficiency Pseudoallescheria Boydii, (2nd time)
Aspergillus fumigatus and Ps aer
after admission
16 F 39 19 17 Resp exac and Lung Ps aer and 1 36 IMV for BAE
haemoptysis pancreatic insufficiency Aspergillus
17 F 18 21 20 Resp exac and Lung Ps aer and MRSA 2 3 NIV and IMV
haemoptysis pancreatic insufficiency
IDDM
Cirrhosis and Portal Htn
18 M 19 12 20 Resp exac and Lung Ps aer and S aureus 30 35 NIV and IMV
Haemoptysis pancreatic insufficiency
19 F 27 16 23 BIH Lung Ps aer and S aureus 6 22 IMV
pancreatic insufficiency
IDDM
20 M 35 23 17 Ascites, small Lung Ps aer and MRSA 1 22 IMV
pneumothorax pancreatic insufficiency
Cirrhosis and Portal Htn
Pt No-Patient Number,
*Admitted to a peripheral hospital for four days prior to admission to RPAH.
Resp Exac – Respiratory Exacerbation, BIH – Benign Intracranial Hypertension, IDDM – Insulin Dependent Diabetes Mellitus, Portal Htn-Portal Hypertension, Ps aer – Pseudomonas
aeruginosa, S aureus – Staphylococcus aureus, MRSA-Methicillin resistant Staphylococcus aureus, CPAP – Continuous Positive Airway Pressure, IMV – Invasive mechanical Ventilation, NIV
– Non-invasive ventilation, BAE – Bronchial Artery Embolization.
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Table 3
Comparison of survivors vs. patients who died
Characteristic Survivors Ns9 Deaths Ns11 Relative risk of death (CI)
FEV -24% predicted1 2 9 3.68 (1.11–16.33)
BMI -18 0 7 3.25 (1.27–3.25)
vived more than 1 year. Five have subsequently under-
gone lung transplantation. Five of the nine patients
(56%) had potentially reversible conditions, namely
pneumothoraces, anaphylaxis, acute variceal bleeding,
and drug overdose (Table 1).
Six of the 15 patients (40%) admitted with respiratory
deteriorations survived and were alive 12 months post
discharge. Of these 15 patients, 10 were admitted with
respiratory exacerbations alone. Nine of these 10 patients
received IMV in ICU with six of these patients also
receiving NIV during their hospital stay.
One patient’s respiratory function deteriorated during
her pregnancy, with her FEV falling from 54% before1
her pregnancy to 26% prior to being admitted to ICU,
in her third admission for RD during the pregnancy. She
was initially treated with NIV, but required an urgent
caesarian section at 30 weeks, delivering a healthy baby
girl weighing 1.6 kg. Following the caesarian section
the patient continued to deteriorate and was intubated
and ventilated. After 1 month of IMV, she was placed
on NIV and was subsequently discharged home with
NIV. Later she underwent successful lung transplantation
and was alive 12 months after discharge. The baby was
admitted to neonatal intensive care but was subsequently
discharged without further complications.
In total three patients were maintained on NIV post
discharge. A fourth patient was still in hospital being
treated with non-invasive ventilation when he received
a lung transplant and is still alive at this time.
Three of the 13 patients admitted with respiratory
exacerbations, had their admission complicated by mas-
sive haemoptysis. All three were intubated and received
NIV (Table 2). Two patients were admitted to ICU
following their haemoptysis, and underwent bronchial
artery embolization (BAE) but died of respiratory failure
despite this. The third patient was already in ICU and
suffered a catastrophic haemoptysis from which she died
suddenly.
Three other patients were admitted to ICU due to CF
related liver disease, two with severe upper gastrointes-
tinal bleeding, secondary to oesophageal varices, and
one due to intractable ascites. Both patients with severe
gastrointestinal bleeding were known to have cirrhosis
and portal hypertension, and preserved lung function,
with an FEV of 88% and 73% predicted, respectively.1
Both required intubation, and ventilation, and blood
transfusion. Both patients also had Linton tubes inserted
urgently, followed by endoscopy and banding of the
varices with effective results. One is alive 6 years later
and the other is doing well 1 year later.
The median length of stay in ICU was 5 days with a
wide range (range 1–51 days, 3–13 interquartile range).
Sixteen of the 20 patients (80%) were admitted to ICU
for less than 2 weeks, with seven surviving. Of the
remaining four two patients died in ICU after 16 and
30 days, respectively. The other two patients survived,
one after a 51 day ICU admission after her caesarian
section. The second patient survived to have his lung
transplant after a prolonged hospitalisation during which
he was admitted to ICU three times for 17 days, 8 days
and 3 days, respectively.
In considering factors that could influence outcomes,
poorer lung function, with an FEV less than 24%1
predicted, and poorer nutritional status, with a BMI of
less than 18 were significantly associated with a higher
chance of death. The relative risk of death for patients
with a FEV -24% predicted was 3.682 (1.11–16.362)1
and the relative risk of death for those with a BMI -
18 was 3.25 (1.98–4.52) (Table 3). In particular it is
noteworthy that no patient with a BMI -18 survived
ICU admission, and that four of the eleven patients who
died were malnourished to the extent that they required
feeding via a percutaneous endoscopic gastrostomy
(PEG) tube, whereas none of the survivors were treated
with enteral feeds. Arterial carbon dioxide tension
(P CO ) on ICU admission did not influence outcome.A 2
4. Discussion
The major finding of our study was that the survival
rate of adult patients admitted to ICU with respiratory
deteriorations has improved when compared to the
earlier study reported by Davis in 1978. Almost half the
patients admitted to ICU in our study survived to
hospital discharge and twelve months following
discharge.
When Davis and di Sant’Agnese w1x evaluated the
outcomes of assisted ventilation for patients with CF in
1978, they reported that the 1 year survival for their
patient group was only 6%. Since then various groups
have reported better outcomes with IMV for patients
with CF who are 5 years and under w13,14x, with
survival rates ranging from 50–100%.
More recently, Berlinski et al. w15x evaluated the
outcome of IMV for 33 CF patients including children
and some adults in acute respiratory failure. They again
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confirmed that infants and young children requiring
IMV, had a favourable prognosis with a mortality rate
of 22%, compared with 75% for the patients ranging
from 5 to 34. Their nested case control study found that
patients with a history of massive haemoptysis and
malnutrition were at significantly increased risk of devel-
oping respiratory failure requiring IMV. In particular
they found that the highest risk was associated with a
history of massive haemoptysis, with a 6-fold increase
risk for needing IMV in this group.
In our series, all three patients who developed hae-
moptysis died, which is keeping with Berlinski’s data.
Although the number of patients involved is small, these
findings suggest that in the context of an exacerbation
requiring ICU admission and IMV, haemoptysis carries
a grave prognosis, contrary to previous literature that
this is a reversible treatable symptom w16,19x. The main
difference between our series and Berlinski’s compared
to previous work, is that we were assessing the impact
of haemoptysis in the setting of a respiratory deteriora-
tion which resulted in invasive mechanical ventilation,
rather than evaluating the impact of isolated haemo-
ptysis.
Our findings are in keeping with a recent case report
w20x of a 26-year-old man with significant lung disease
(FEV 31% predicted) who was admitted to ICU on1
two occasions initially with haematemesis and later with
massive haemoptysis requiring BAE and IMV. He did
survive the 28 day ICU admission, and was discharged
on day 46, but died at home 12 days later, highlighting
the fact that massive haemoptysis requiring IMV in
combination with significant comorbidities, such as poor
baseline lung function, a respiratory deterioration, or
severe liver disease, carries a grave prognosis, even with
ICU treatment.
Our survival rate for patients admitted with RD was
similar to Sood et al., but appeared to be higher than
Berlinksi’s data regarding adults. However, Sood et al.
w16x did not find any particular factors were useful in
predicting survival, where as we found that an FEV of1
-24% predicted, and BMI of -18 were significantly
associated with a poorer chance of survival.
Inherent differences between the patient populations
and policies with regard to the option of transplantation
in mechanically ventilated patients may have contributed
to the differing results between these three studies, as
Berlinki’s group only evaluated patients requiring IMV
and eight of the 23 survivors (35%) in Sood’s paper
underwent lung transplantation while still being mechan-
ically ventilated.
There has been increasing evidence in recent years
w21,22x that poorer nutritional status is independently
predictive of mortality in patients with CF. Our findings,
in keeping, with Berlinski’s group suggest that nutrition-
al status is an significant risk factor for developing
respiratory failure and an important prognostic indicator
of outcome for ICU admission.
Our findings that an FEV less than 24% predicted1
was associated with a worse outcome, is in keeping
with previous work w23x relating impaired lung function
to mortality rate.
The survival of both our patients with acute variceal
bleeding is in keeping with previous work w24x, sug-
gesting that in CF related cirrhosis, variceal bleeding is
the main early complication whereas liver failure occurs
later in the course of the disease, and hence management
of this bleeding is often successful in stabilizing patients
for many years.
It could be construed that the retrospective nature and
modest sample size of this study were limitations.
However, it is highly unlikely that a prospective random-
ised study related to ICU care vs. no ICU care will ever
be undertaken. In addition, our report is the 15 year
experience from a unit, willing to utilise ICU services.
In summary, the major findings of this study were
that in one Australian centre the outcomes for patients
with CF who have been admitted to ICU, have improved
considerably when compared with those documented by
di Sant’Agnese in 1978. In particular for patients with
potentially reversible conditions, such as pneumothorax,
anaphylaxis and variceal bleeding the outcomes were
very good. In addition, our results suggest that special
note should be taken of the BMI and FEV % predicted1
when making the difficult decision as to whether a
patient with CF can be successfully managed in the
ICU.
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